Biotech Funding Trends

Alexandra Carina Gruber, born in 1971 in Vienna, Austria, has been working in the pharmaceutical industry for the past 12 years, where she has held various marketing and business development positions and developed a profound expertise in the marketing and licensing of biotech and generic products. She is currently Director of Business Development & Marketing at BIOCRATES Life Sciences in Innsbruck Austria.

Wer bekommt im Biotech-Sektor das Geld? Aktuellen Trends der Vergabe von Investmentkapital ist die Autorin dieses Bandes auf der Spur, gestützt auf Interviews mit Vertretern beider Seiten am Verhandlungstisch. Fallstudien illustrieren die Spannungen, die durch Unterschiede in Background und Erwartungen der Verhandlungspartner zustande kommen. Das Buch zeigt Möglichkeiten auf, diese Vorurteile zu bewältigen, damit die finanzierten Unternehmen erfolgreich am Markt bestehen können.Unentbehrlich für Unternehmer aus der Biotech-Sparte und interessierte Investoren; empfehlenswert auch für Studenten, die sich beruflich in Richtung Industrie orientieren.

Based on interviews with successful biotech entrepreneurs and high-level investors as well as case studies, this title provides a comprehensive overview of current trends in biotech funding. In particular, it illustrates the tensions between both sides based on their different backgrounds and expectations.

INTRODUCTIONDevelopment of the Private Equity and Venture Capital MarketDevelopment of the Biotech IndustryMETHODOLOGYFormulating the Research GoalConducting the StudyEvaluating the ResultsDATA ANALYSIS AND INTERPRETATION OF RESULTSDescription of Interview PartnersMajor Characteristics of an EntrepreneurMajor Characteristics of a Venture CapitalistThe Most Important Partnering CriteriaFinancing ModelsBiotech Research AreasAlliances and Funding in the Early StageAlliances and Funding in the Late StageExit RoutesPrimary Causes of FailureBest-practice Countries for Funding Biotech Start-upsStriking Differences between the US and European Venture Capital MarketsBIOTECH CASE STUDIESAUSTRIANOVA Biomanufacturing AGAVIR Green Hills Biotechnology AGEUCODIS GmbHIntercell AGonepharm Research & Development GmbHSUMMARY AND CONCLUSIONSThe Challenge: When Science Meets BusinessChecklistsFinal ObservationsOUTLOOK AND RECOMMENDATIONSEPILOGUEREFERENCESAPPENDICES